Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2005-08-02
2005-08-02
Spector, Lorraine (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C530S324000
Reexamination Certificate
active
06923968
ABSTRACT:
The present invention relates to a novel method for treating a patient that has osteoporosis and the patient may be having administered cyclase activating parathyroid hormone (CAP) or analogues. The patient receives an administration of a cyclase inhibiting parathyroid hormone peptide (CIP) having an amino acid sequence from between (SEQ ID NO:1 [PTH2-84]) and (SEQ ID NO:3 [PTH34-84]) (i.e., a contiguous portion of PTH having an amino acid sequence set forth in SEQ ID NO:5 (PTH1-84), having the N-terminal amino acid residue starting at any position spanning from position 2 through position 34 of the PTH1-84, and the C-terminal amino acid residue ending at position 84 of the PTH1-84), (preferably (SEQ ID NO:2 [PTH3-84]) and (SEQ ID NO:8 [PTH28-84])), or a conservatively substituted variant thereof exhibiting parathyroid hormone (PTH) antagonist activity in a therapeutically effective, but non-toxic amount that reduces the occurrence of hypercalcemia or osteosarcoma in the patient resulting from the administration of CAP, and yet, through a CAP rebound effect, is effective in itself in the treatment of osteoporosis.
REFERENCES:
patent: 4369138 (1983-01-01), Lindall
patent: 4423037 (1983-12-01), Rosenblatt et al.
patent: 4508828 (1985-04-01), Lindall et al.
patent: 4656250 (1987-04-01), Morita et al.
patent: 5856138 (1999-01-01), Fukuda
patent: 6030790 (2000-02-01), Adermann et al.
patent: 6051686 (2000-04-01), Krstenansky et al.
patent: 33 47 548 (1985-07-01), None
patent: 44 34 551 (1996-04-01), None
patent: 0 783 522 (2001-12-01), None
patent: WO 91 06564 (1991-05-01), None
patent: EP 0 451 867 (1991-11-01), None
patent: WO 93 06845 (1993-04-01), None
patent: WO 94 03201 (1994-02-01), None
Chorey et al., Biochemistry (1990) 29:1580-1586.
Hoare et al., Journal of Biological Chemistry (2000) 275(35):27274-27283.
International Search Report for PCT/US02/25348, mailed on Jul. 26, 2004, 4 pages.
Jonsson et al., Endocrinology (2001) 142(2):704-709.
Pausova et al., Mammalian Genome (1995) 6:408-414.
Takasu et al., Journal of Bone Mineral Metabolism (1994) 12(Suppl.1):S131-S134.
Yu et al., Endocrinology (1997) 138(8):3085-3092.
U.S. Appl. No. 09/231/422, filed Jan. 14, 1999.
U.S. Appl. No. 09/344,639, filed Jun. 26, 1999.
U.S. Appl. No. 09/928,047, filed Aug. 10, 2001.
U.S. Appl. No. 09/636,530, filed Aug. 10, 2001.
U.S. Appl. No. 09/636,531, filed Aug. 10, 2000.
U.S. Appl. No. 10/002,818, filed Nov. 2, 2001.
U.S. Appl. No. 60/224,396, filed Aug. 10, 2000.
U.S. Appl. No. 09/928,048, filed Aug. 10, 2001.
U.S. Appl. No. 09/323,606, filed Jun. 2, 1999.
Aldermann et al., in: Innovations and Perspectives in Solid Phase Synthesis, Epton (ed.). Mayflower World Wide, Birmingham (1994) pp. 429-432.
Atkinson et al., Journal of Immunoassay (1982) 3(1):31-51.
Blind et al., Clin. Chem. (1987) 33(8):1376-1381.
Bowie et al., Science (1990) 247:1306-1310.
Brossard et al., Journal of Clinical Endocrinology and Metabolism (1996) 81(11):3923-3929.
Campbell, Monoclonal Antibody and Immunosensor Technology, in Laboratory Techniques in Biochemistry and Molecular Biology, van der Vliet (ed.), Elsevier (1991) pp. 1-11, 42-45.
Caporale and Rosenblatt, Paraththyroid Hormone Antagonists Effective in vivo, in: Advances in Experimental Medicine and Biology, New York (1986) pp. 315-327.
Clinical Chemistry (1999) 45(6)Suppl:A97 b. Abstract Nos. 339-341.
D'Amour et al., Am. J. Physiol. (1986) 251:E680-E687.
Daniel et al., Virology (1994) 202:540-549.
Divieti, P. et al. (2001).J Bone Miner Res2001:Suppl 1, S307.
Faugere, M.C. et al. (2001).Kidney International60:1-460-1-468.
Faugere, M.C. et al.Nephrology, Bone&Mineral MetabolismA3995.
Fischer et al., The Journal of Clinical Investigation (1974) 54:1382-1394.
Gao et al., Clinica Chimica Acta (1996) 245:39-59.
Goodman, W. et al. (2000).NEJM342:20, 1478-1483.
Gordon et al., Parathyroid Hormone Domain for Protein Kinase C Stimulation Located within Amphiphilic Helix, in: Peptides: Chemistry and Biology, Proceedings of the Twelfth American Peptide Symposium, Jun. 16-21, 1991. Cambridge, MA, Smith and Rivier (eds.) Escom Science Publishers (1992) pp. 37-39.
Hashimoto et al., Journal of Cardiovascular Pharmacology (1981) 3(4):668-676.
Hehrmann et al., Journal of Immunoassay (1980) 1(2):151-174.
John et al., Journal of Clinical Endocrinology and Metabolism (1999) 84(11):4287-4290.
LePage et al., Clin. Chem. (1998) 44:805-810.
Logue et al., Journal of Immunological Methods (1991) 137:159-166.
Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(1):197-204.
Mägerlein et al., Arzneim.-Forsch. Drug Res. (1998) 48(11):783-787.
Mallette, Journal of Clinical Endocrinology and Metabolism (1980) 50(1):201-203.
Nakamura et al., Endocrinol. JPN (1981) 28(4):547-549.
Ngo et al., The Protein Folding Problem and Tertiary Structure Prediction. Merz et al., (eds.). Birkhäuser Boston (1994) pp. 492-495.
Niall et al., Proc. Natl. Acad. Sci. USA (1974) 71(2):384-388.
Nussbaum et al., Chemical Abstracts (1982) 96(5):181-192.
Pang et al., Pharmacol. Exp. Ther. (1981) 216(3):567-571.
Podbesek et al. (1983).Endocrinology112(3):1000-1006.
Qi et al., Am. J. Kidney Dis. (1995) 26:622-631.
Quarles et al., J. Clin. Endocrinol. Metab. (1992) 75:145-150.
Stadler, Homologous Radioimmunoassay for Human Parathyroid Hormone (Residues 1-34) with Biotinylated Peptide as Tracer, in Calcium Regulating Hormones, Vitamin D Metabolites, and Cyclic AMP Assays and their Clinical Application, Schmidt-Gayk et al., (eds.). Berlin/Heidelberg, Springer, (1990) pp. 137-150.
Tampe et al., J. Immunoassay (1992) 13(1):1-13.
Visser et al., Acta Endocrinology (1979) 90:90-102.
Wingender et al., Structure-Function Relationship in Parathyroid Hormone in: Advances in Protein Design, International Workshop, Blöcker et al. (eds.). VCH (1988) pp. 167-176.
Zanelli et al., Journal of Immunoassay (1983) 4(2):175-206.
Zemplar package insert. Abbott Reference (1998), 06-9998-R1-Rev. Roche Laboratories.
Jiang Dong
Morrison & Foerster / LLP
Scantibodies Laboratory, Inc.
Spector Lorraine
LandOfFree
Cyclase inhibiting parathyroid hormone antagonists or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclase inhibiting parathyroid hormone antagonists or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclase inhibiting parathyroid hormone antagonists or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3491931